Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium.
BACKGROUND
Genetic mutations of dystrophin and associated glycoproteins underlie cell degeneration in several inherited cardiomyopathies, although the precise physiological role of these proteins remains under discussion. We studied the distribution of dystrophin in relation to the force-transducing vinculin-rich costameres in left ventricular cardiomyocytes from normal and failing human hearts to further elucidate the function of this protein complex.


RESULTS
Single- and double-label immunoconfocal microscopy and parallel high-resolution immunogold fracture-label electron microscopy were used to localize dystrophin and vinculin in human left ventricular myocytes from normal (n=6) and failing hearts (idiopathic dilated cardiomyopathy, n=7, or ischemic heart disease, n=5). In control cardiomyocytes, dystrophin had a continuous distribution at the peripheral sarcolemma, with concentrated bands corresponding to the vinculin-rich costameres. Intracellular labeling extended along transverse (T) tubule membranes. Fracture-label confirmed this distribution, showing significantly greater label on plasma membrane fractures overlying I-bands (I-band 4.1+/-0.3 gold particles/micrometer A-band 3.3+/-0.2 gold particles/micrometer mean+/-SE, P=0.02). Hypertrophied myocytes from failing hearts showed maintenance of this surface distribution except in degenerating cells; there was a clear increase in intracellular dystrophin label reflecting T-tubule hypertrophy.


CONCLUSIONS
Dystrophin partially colocalizes with costameric vinculin in normal and hypertrophied myocytes, a distribution lost in degenerating cells. This suggests a primarily mechanical role for dystrophin in maintenance of cell membrane integrity in normal and hypertrophied myocytes. The presence of dystrophin in the cardiac T-tubule membrane, in contrast to its known absence in skeletal muscle T-tubules, implies additional roles for dystrophin in membrane domain organization.
Kaprielian
R R
RR
Cardiac Medicine, The National Heart and Lung Institute, Imperial College School of Medicine, London, England.
Stevenson
S
S
Rothery
S M
SM
Cullen
M J
MJ
Severs
N J
NJ
D000328:Adult; D000906:Antibodies; D003598:Cytoskeletal Proteins / Q000032:analysis / Q000276:immunology; D049030:Dystroglycans; D016189:Dystrophin / Q000032:analysis* / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D005614:Freeze Fracturing; D006333:Heart Failure / Q000473:pathology*; D006352:Heart Ventricles / Q000737:chemistry / Q000473:pathology; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis / Q000276:immunology; D018613:Microscopy, Confocal; D008875:Middle Aged; D018485:Muscle Fibers, Skeletal / Q000737:chemistry* / Q000473:pathology / Q000648:ultrastructure; D009206:Myocardium / Q000737:chemistry / Q000473:pathology*; D012508:Sarcolemma / Q000737:chemistry* / Q000473:pathology / Q000648:ultrastructure; D016596:Vinculin / Q000032:analysis / Q000276:immunology
D000906:Antibodies; D003598:Cytoskeletal Proteins; C483081:DAG1 protein, human; D016189:Dystrophin; D008562:Membrane Glycoproteins; D016596:Vinculin; D049030:Dystroglycans